Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections

Hospices Civils de Lyon1,130 enrolled

Overview

the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection

Daptomycin is widely used in osteoarticular infections (IOA), as an alternative to vancomycin, and recommended for this use by various learned societies including the Infectious Diseases Society of America (IDSA) in 2013. Tolerance to daptomycin is generally favorable, with in particular better renal tolerance than vancomycin. However, two rare and potentially severe side effects have been described with this antibiotics: muscle toxicity and eosinophilic pneumonia.

Study Type

OBSERVATIONAL

Enrollment

1,130

Conditions

Dactinomycin Adverse Reaction Bone and Joint Infection

Interventions

patients having had BJI or PJI treated with daptomycinOTHER

patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have had an osteoarticular infection, treated with daptomycin, with at least one blood test for daptomycin performed Exclusion Criteria: * Patients who objected to participating in the study * Absence of blood dosage of daptomycin

Locations (1)

Hospices Civils de Lyon

Lyon, France

RECRUITING